Please try another search
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
Manuel C. Aivado | 54 | 2014 | Director |
Alan F. List | 69 | 2018 | Member of Scientific Advisory Board |
Brian J. Druker | 68 | 2018 | Member of Scientific Advisory Board |
Reinhard J. Ambros | 69 | 2013 | Independent Lead Director |
Carol L. Prives | - | 2018 | Member of Scientific Advisory Board |
Josef H. von Rickenbach | 69 | 2019 | Independent Chairman |
Ulrich Steidl | - | - | Member of Scientific Advisory Board |
Alan A. Musso | 62 | 2023 | Independent Director |
James Brian Windsor | 58 | 2023 | CEO, President & Director |
William Carl Fairey | 59 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review